Cell energy latest in anti-aging battle

Nurigene skin care line is part of the money making arm of a US biotech company that uses the same technology to develop drugs against neurodegenerative diseases such as Parkinson's and Huntington's disease. According to the company the product line has been clinically proven to increase cell turnover, improve skin firmness and elasticity, and improve the skin's ability to retain moisture. Cellular energy system​ Avicena, the company behind the technology, focus on the body's creatine kinase and creatine transporter systems. Creatine is a compound occurring in muscle, brain, heart, retina and skin tissue cells. In these cells the creatine is transported from the cytoplasm into the mitochondria, where a phosphate group is added to the molecule. The compound is stored in this form until energy is needed. At this point the phosphate group is given to an adenosine diphosphate molecule resulting in adenoisine tripohosphate - the body's basic energy molecule. Avicena has been concentrating on regulating this energy system, as a lack of cellular energy causes certain cells to degenerate at a more rapid rate, linked to the onset of certain neurodegenerative diseases like Parkinson's. ​ Cellular energy and the skin ​ Avicena claim that the skin also benefits from regulating the cell's energy system, and they have patented the core technology in Nurigene as Advanced Skin Nourishment. The range promotes optimal cellular regeneration by providing critical nourishment to the skin cell's as they are growing, according to the company. Clinical trials were carried out that according to the company, demonstrate that Nurigene leads to significant improvements in skin cell turnover, skin firmness, skin elasticity and the skin's ability to retain moisture. Avicena currently has a range of dermaceutical ingredients and formulations on the market, which it sells to dermaceutical and cosmoceutical firms. This, along with the Nurigene range, allows the company to exploit the large skin care market in the US and the financial benefits that this may hold. "By applying our proprietary technology platform to the development of next-generation dermaceuticals, we are able to tap into the growing $9 billion U.S. skin care market",​ Belinda Tsao Nivaggioli, Avicena's CEO stated.